- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00904098
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine
February 12, 2010 updated by: Endo Pharmaceuticals
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine
Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the early stage (International Headache Society [IHS] Grade 1) of MM compared with patients' current treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
192
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Stratford, Connecticut, United States
-
-
Florida
-
Clearwater, Florida, United States
-
Jacksonville, Florida, United States
-
Largo, Florida, United States
-
Tampa, Florida, United States
-
-
New Jersey
-
Blackwood, New Jersey, United States
-
-
New York
-
New York, New York, United States
-
Plainview, New York, United States
-
Vestal, New York, United States
-
-
North Carolina
-
Burlington, North Carolina, United States
-
Raleigh, North Carolina, United States
-
Salisbury, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
West Chester, Ohio, United States
-
-
Pennsylvania
-
Norristown, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
St. Petersburg, Pennsylvania, United States
-
Upland, Pennsylvania, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Had MM headaches occurring between Day -2 and Day +3 of menses
- Had at least one year history of MM headaches
- Had at least 8 MM headaches in the previous 12 menstrual cycles (1 year)
- Had regular predictable menstrual periods (28 ± 4 days)
Exclusion Criteria:
- Had a history of more than 15 headache days per month
- As part of current MM treatment, used intermittent prevention with an analgesic (e.g., naproxen for 5 days to prevent the onset of MM)
- Had a history of myocardial infarction, ischemic heart disease (or presented with symptoms or signs compatible with ischemic heart disease), coronary vasospasm (including Prinzmetal's variant angina), other significant underlying cardiovascular disease, or peripheral vascular disease
- Had significant cerebrovascular disease, including basilar or hemiplegic migraine
- Had uncontrolled hypertension: systolic blood pressure >180mmHg and diastolic blood pressure >95mmHg
- Had severe hepatic or renal insufficiency
- Used an analgesic medication (including both prescription and over-the-counter) for any reason >50% of days per month
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Frovatriptan
Frovatriptan 2.5 mg oral tablet
|
This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:
|
Active Comparator: Usual Care
Usual care includes the current treatment used to treat all episodes of migraine headache
|
Current treatment used to treat all migraine headaches
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Headache pain severity
Time Frame: Visit - V1(Day 0), V2 (Day 28), V3 (Day 56)
|
Visit - V1(Day 0), V2 (Day 28), V3 (Day 56)
|
Secondary Outcome Measures
Outcome Measure |
---|
Patient satisfaction with treatment
|
Occurrence and severity of MM symptoms associated with migraine headache pain (nausea, vomiting, photophobia, and phonophobia)
|
Occurrence and severity of functional impairment during menstrual migraine
|
Use of rescue medication and additional frovatriptan dose
|
Patient preference of current vs. study treatment (end of study only)
|
Safety as assessed by occurrence of AEs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
February 1, 2006
Study Completion (Actual)
February 1, 2006
Study Registration Dates
First Submitted
May 15, 2009
First Submitted That Met QC Criteria
May 18, 2009
First Posted (Estimate)
May 19, 2009
Study Record Updates
Last Update Posted (Estimate)
February 15, 2010
Last Update Submitted That Met QC Criteria
February 12, 2010
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Menstruation Disturbances
- Migraine Disorders
- Headache
- Premenstrual Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Serotonin Agents
- Serotonin Receptor Agonists
- Frovatriptan
Other Study ID Numbers
- EN3266-401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menstrual Migraine (MM) Headaches
-
Scott and White Hospital & ClinicUnknownMenstrual Migraines | Menstrual Bleeding | Menstrual SpottingUnited States
-
Gazi UniversityRecruitingHeadache | Headache Disorders | Headache, Migraine | Headaches Chronic | Headache, Tension | Headaches MuscularTurkey
-
University of Notre Dame AustraliaUnknown
-
Memorial Medical CenterUnited States Department of DefenseCompletedMigraine HeadachesUnited States
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Gazi UniversityRecruitingHeadache | Headache Disorders | Headache, Migraine | Headaches Chronic | Headache, Tension | Headaches MuscularTurkey
-
POZENCompletedMigraine HeadachesUnited States
-
POZENCompletedMigraine HeadachesUnited States
-
University of SaskatchewanSaskatchewan Health Research FoundationCompleted
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCCompleted
Clinical Trials on Frovatriptan
-
Endo PharmaceuticalsCompleted
-
Endo PharmaceuticalsVernalis (R&D) LtdCompletedMigrainePoland, United Kingdom, South Africa, Hungary, Germany
-
Scott and White Hospital & ClinicEndo PharmaceuticalsCompletedPrevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals (MAM)Bleeding | Migraines | SpottingUnited States
-
ClinvestEndo PharmaceuticalsCompletedMigraineUnited States
-
SK Chemicals Co., Ltd.Completed
-
Endo PharmaceuticalsVernalis (R&D) LtdCompletedMenstrually Associated MigraineUnited States
-
Thomas Jefferson UniversityCompleted
-
University of CalgaryAlberta Health servicesCompletedMedication Overuse Headache | Analgesic Overuse HeadacheCanada
-
Assiut UniversityNot yet recruitingCorneal Higher-order AberrationsEgypt
-
Seattle Nuclear MedicineCompletedCancer | Bone MetastasesUnited States